Author(s)

Jessica L. Chauvin

Affiliation(s)

Louisiana State University, School of Medicine, New Orleans, Louisiana.

Corresponding Author

Jessica L. Chauvin

ABSTRACT

Psoriasis and atherosclerosis are both chronic inflammatory diseases, morphologically manifested as "plaques", but the affected target organs are different. Pro Clinical epidemiological studies suggest that there is a correlation between psoriasis and atherosclerosis. Now, from the perspective of their immunological mechanisms and inflammatory pathways, we will analyze their immunological Do a literature review on the relationship between pathogenesis.

KEYWORDS

Psoriasis; Atherosclerosis; Immunology; Pathogenesis

CITE THIS PAPER

Jessica L. Chauvin. The link between psoriasis and the immunological pathogenesis of atherosclerosis. Journal of Pharmaceutical and Medical Research. 2023, 5(2): 12-16. DOI:10.61784/jpmr231221.

REFERENCES

[1] Parisi R, Symmons DP, Griffiths CE, et al. Global epide- miology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol, 2013, 133 (2): 377-385.

[2] Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol, 2014, 32: 227-255.

[3] Monteleone G, Pallone F, MacDonald TT, et al. Psoriasis:from pathogenesis to novel therapeutic approaches. ClinSci(Lond), 2011, 120(1): 1-11.

[4] Reich K. The concept of psoriasis as a systemic inflamma- tion: implications for disease management. J Eur Acad Dermatol Venereol, 2012, 26(Suppl 2): 3-11.

[5] Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol, 2011, 12(3): 204-212.

[6] Libby P. History of discovery: inflammation of atherosclerosis. Arterioscler Thromb Vasc Biol, 2012, 32(9): 2 045-051.

[7] Gelfand JM, Neimann AL, Shin DB, et al. Riskof myocar- dial infarction in patients with psoriasis. JAMA, 2006, 296(14): 1 735-741.

[8] Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol, 2009, 23(11): 1 311-315.

[9] Kimball AB, Guerin A, Latremouille-Viau D, et al. Coro- nary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med, 2010, 123 (4): 350-357.

[10] Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med, 2011, 270(2): 147-157.

[11] Samarasekera EJ, Neilson JM, Warren RB, et al. Inci- dence of cardiovascular disease in individuals with psoria- sis: a systematic review and meta-analysis. J Invest Dermatol, 2013, 133(10): 2 340-346.

[12] Xu T, Zhang YH. Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies. Br J Dermatol, 2012, 167(6): 1 345-350.

[13] Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol, 2009, 145(6): 700-703.

[14] Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol, 2009, 129(10): 2 411-418.

[15] Kaye JA, Li L, Jick SS. Incidence of risk factors for myo- cardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol, 2008, 159 (4): 895-902.

[16] Shaharyar S, Warraich H, McEvoy JW, et al. Subclinical cardiovascular disease in plaque psoriasis: association or causal link. Atherosclerosis, 2014, 232(1): 72-78.

[17] Gupta Y, Moller S, Zillikens D, et al. Genetic control of psoriasis is relatively distinct from that of metabolic syn- drome and coronary artery disease. Exp Dermatol, 2013, 22(8): 552-553.

[18] Lu YC, Chen HY, Nikamo Pin, et al.Association self cardiovascular and metabolic disease gene is with psoriasis 1 J 1 J Invest Dermatol, 2013, 133: 836-839.

[19] Koch M, Baurecht H, RiedJS, et al. Psoriasis and cardi- ometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol, 2015, 135 (5): 1283-293.

[20] Gilliet M, Lande R. Antimicrobial peptides and self-DNA in autoimmune skin inflammation. Curr Opin Immunol, 2008, 20: 401-407.

[21] Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 2007, 449: 564-569.

[22] Ganguly D, Chamilos G, Lande R, et al. Self-RNA-anti- microbial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med, 2009, 206: 1983-994.

[23] Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature, 2007, 445 (7130):866-873.

[24] Skalen K, Gustafsson M, Rydberg EK, et al. Subendothe- lial retention of atherogenic lipoproteins in early athero- sclerosis. Nature, 2002, 417: 750-754.

[25] Tabas I, Williams KJ, BorenJ. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation, 2007, 116: 1 832-844.

[26] Yan ZQ, Hansson GK. Innate immunity, macrophage acti- vation, and atherosclerosis. Immunol Rev, 2007, 219: 187-203.

[27] Ketelhuth DF, Hansson GK. Modulation of autoimmunity and atherosclerosis-common targets and promising transla- tional approaches against disease. Circ J, 2015, 79 (5): 924-933.

[28] Ghazizadeh R, Shimizu H, Tosa M, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci, 2010, 7(5): 284-289.

[29] Buckner JH. Mechanisms of impaired regulation by CD4+ CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol, 2010, 10: 849-859.

[30] Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and targettissue CD4+ CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained patho- geniceffector T cell proliferation. J Immunol, 2005, 174: 164-173.

[31] Alexandroff AB, Pauriah M, Camp RD, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol, 2009, 161(1): 1-7.

[32] ArmstrongAW, HarskampCT, Armstrong EJ. The associa- tion between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes, 2012, 2: e54.

[33] Kumar S, Han J, Li T, et al. Obesity, waist circumfer- ence, weight change and the risk of psoriasis in USwomen. J Eur Acad Dermatol Venereol, 2013, 27 (10): 1 293-298.

[34] Kaye JA, Li L, Jick SS. Incidence of risk factors for myo- cardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol, 2008, 159 (4):895-902.

[35] Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr, 2014, 105(1): 31-44.

[36] Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and sys- temic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol, 2010, 130(7): 1 785-796.

[37] Siegel D, Devaraj S, Mitra A, et al. Inflammation, ather- osclerosis, and psoriasis. Clin Rev Allergy Immunol, 2013, 44(2): 194-204.

[38] Chen L, Chen R, Wang H, et al. Mechanisms linking in- flammation to insulin resistance. Int J Endocrinol, 2015, 2015: 508 409.

[39] Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Auto- immun Rev, 2014, 13(9): 981-1 000.

[40] Boehncke WH, Boehncke S, Tobin AM, et al. The ‘pso- riatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol, 2011, 20 (4): 303-307.

[41] Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol, 2007, 157(6): 1 249-251.

[42] Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol, 2010, 24(12): 1 386-394.

[43] Garbaraviciene J, Diehl S, Varwig D, et al. Platelet P-se- lectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis.Exp Dermatol, 2010, 19(8): 736-741.

[44] Wolfram JA, Diaconu D, Hatala DA, et al. Keratinocyte but not endothelial cell-specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol, 2009, 174(4): 1 443-458.

[45] Wang Y, Gao H, Loyd CM, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol, 2012, 132 (8): 2067-075.

[46] Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G, et al. Molecular and cellular mechanisms linking inflammation to insulin resistance and beta-cell dysfunction. Transl Res, 2016, 167(1): 228-256.

[47] Vanhoutte PM, Shimokawa H, Feletou Also al.Endothe- lial dysfunction and vascular disease -a thirthieth anniv er- sary update J 1 Acta Phy siologica (in press), 2015.

[48] Patel TP, Rawal K, Bagchi AK, et al. Insulin resistance: an additional risk factor in the pathogenesis of cardiovas- cular disease in type 2 diabetes. Heart Fail Rev (in press), 2015.

[49] Steyers CM, Miller FJ Jr. Endothelial dysfunction in chro- nic inflammatory diseases. Int J Mol Sci, 2014, 15 (7): 11 324-349.

[50] Grayson M. Psoriasis. Nature, 2012, 492(7429): S49.